Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors
February 23, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present at Upcoming Investor Conferences
February 19, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints Linda Richardson as Chief Commercial Officer
February 17, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept’s Executive Leadership Team NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intercept...
Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
February 11, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Company Statement on Analyst Note
January 27, 2021 13:35 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
January 11, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Pharmaceuticals Announces Leadership Transition
December 10, 2020 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Jerry Durso Appointed CEO Effective January 1, 2021;Founder, President and CEO Mark Pruzanski to Continue as Board Member and Advisor NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Intercept...
Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 07:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH
November 16, 2020 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...